Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach

Intensive Care Medicine

Volumn 43, Issue 10, 2017, Pages 1464-1475

  Bassetti, Matteo ^a   Poulakou, Garyphallia ^b   Ruppe, Etienne ^c   Bouza, Emilio ^d,e,f,g   Van Hal, Sebastian J ^h   Brink, Adrian ^i,j  

^a Università di Udine e Azienda Sanitaria Universitaria Integrata di Udine   (Italy)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f SCHOOL OF MEDICINE   (Spain)

^g INSTITUTO DE SALUD CARLOS III   (Spain)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ MILPARK HOSPITAL   (South Africa)

^j UNIVERSITY OF CAPE TOWN   (South Africa)

more..

Author keywords

Antibiotics; Antimicrobial resistance; Diagnostic test; Microbiota; Phage therapy; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; VACCINE; ANTIINFECTIVE AGENT;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; DIAGNOSTIC TEST; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; HEALTHCARE ASSOCIATED INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INTENSIVE CARE UNIT; INTESTINE FLORA; MEDICAL LITERATURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; PASSIVE IMMUNIZATION; PHAGE THERAPY; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PUBLIC HEALTH; REVIEW; STAPHYLOCOCCUS AUREUS; ANTIMICROBIAL STEWARDSHIP; CLINICAL PRACTICE; CROSS INFECTION; DRUG EFFECT; FORECASTING; GLOBAL HEALTH; HEALTH CARE POLICY; HUMAN; MICROFLORA; TRENDS;

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL STEWARDSHIP; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FORECASTING; GLOBAL HEALTH; HEALTH POLICY; HUMANS; INFECTION CONTROL; INTENSIVE CARE UNITS; MICROBIOTA; PHAGE THERAPY; PRACTICE PATTERNS, PHYSICIANS';

EID: 85025477641     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-017-4878-x     Document Type: Review

References (82)

1. Sender R, Fuchs S, Milo R (2016) Revised estimates for the number of human and bacteria cells in the body. PLoS Biol 14:e1002533. doi:10.1371/journal.pbio.1002533
2. Bassetti M, Carnelutti A, Peghin M (2017) Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in Gram-negative bacterial infections. Expert Rev Anti Infect Ther 15(1):55–65. doi:10.1080/14787210.2017.1251840
3. Ruppé É, Woerther PL, Barbier F (2015) Mechanisms of antimicrobial resistance in Gram-negative bacilli. Ann Intensive Care 5:21. doi:10.1186/s13613-015-0061-0
4. Karanika S, Karantanos T, Arvanitis M et al (2016) Fecal colonization with extended spectrum beta-lactamase-producing Enterobacteriaceae and risk factors among healthy individuals: a systematic review and meta analysis. Clin Infect Dis 63:310–318
5. Lee BY, Bartsch SM, Wong KF et al (2016) The potential trajectory of carbapenem-resistant Enterobacteriaceae, an emerging threat to health-care facilities, and the impact of the centers for disease control and prevention toolkit. Am J Epidemiol 183(5):471–479
6. Teerawattanapong N, Kengkla K, Dilokthornsakul P et al (2017) Prevention and control of multidrug-resistant Gram-negative bacteria in adult intensive care units: a systematic review and network meta-analysis. Clin Infect Dis 64:51–60
7. Kanamori H, Parobek CM, Juliano JJ et al (2017) A prolonged outbreak of KPC-3-producing Enterobacter cloacae and Klebsiella pneumoniae driven by multiple mechanisms of resistance transmission at a large academic burn center. Antimicrob Agents Chemother 61(2):e01516-16. doi:10.1128/AAC.01516-1
8. Watkins RR, Smith TC, Bonomo RA (2016) On the path to untreatable infections: colistin use in agriculture and the end of “last resort” antibiotics. Expert Rev Anti Infect Ther 14:785–788. doi:10.1080/14787210.2016.1216314
9. Newitt S, Myles PR, Birkin JA et al (2015) Impact of infection control interventions on rates of Staphylococcus aureus bacteraemia in National Health Service acute hospitals, East Midlands, UK, using interrupted time-series analysis. J Hosp Infect 90:28–37. doi:10.1016/j.jhin.2014.12.016
10. Grundmann H, Schouls LM, Aanensen DM et al (2014) The dynamic changes of dominant clones of Staphylococcus aureus causing bloodstream infections in the European region: results of a second structured survey. EuroSurveill 19:20987
11. Andrey DO, François P, Manzano C et al (2017) Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals. Eur J Clin Microbiol Infect Dis 36:343–350. doi:10.1007/s10096-016-2807-5
12. Harbarth S, Samore MH (2005) Antimicrobial resistance determinants and future control. Emerg Infect Dis 11:794–800. doi:10.3201/eid1106.050167
13. van Bunnik BAD, Woolhouse MEJ (2017) Modelling the impact of curtailing antibiotic usage in food animals on antibiotic resistance in humans. R Soc Open Sci 4:161067. doi:10.1098/rsos.161067
14. Murray E, Holmes A (2012) Addressing healthcare-associated infections and antimicrobial resistance from an organizational perspective: progress and challenges. J Antimicrob Chemother 67[Suppl 1]:i29–i36. doi:10.1093/jac/dks200
15. Brink AJ, Messina AP, Feldman C et al (2017) From guidelines to practice: a pharmacist-driven prospective audit and feedback improvement model for peri-operative antibiotic prophylaxis in 34 South African hospitals. J Antimicrob Chemother 72:1227–1234. doi:10.1093/jac/dkw523
16. Mellmann A, Bletz S, Boking T et al (2016) Real-time genome sequencing of resistant bacteria provides precision infection control in an institutional setting. J Clin Microbiol 54:2874–2881. doi:10.1128/JCM.00790-16
17. Bilinski J, Grzesiowski P, Muszynski J et al (2016) Fecal microbiota transplantation inhibits multidrug-resistant gut pathogens: preliminary report performed in an immunocompromised host. Arch Immunol Ther Exp 64:255–258
18. Dellinger RP, Levy MM, Rhodes A et al (2013) Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
19. Cambray G, Sanchez-Alberola N et al (2014) Prevalence of SOS-mediated control of integron integrase expression as an adaptive trait of chromosomal and mobile integrons. Mob DNA 2011(2):6. doi:10.1186/1759-8753-2-6
20. Girmenia C, Viscoli C, Piciocchi A et al (2015) Management of carbapenem resistant Klebsiella pneumoniae infections in stem cell transplant recipients: an Italian multidisciplinary consensus statement. Haematologica 100:e373–e376
21. Patel R (2015) MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem 61:100–111
22. Bauer KA, Perez KK, Forrest GN et al (2014) Review of rapid diagnostic tests used by antimicrobial stewardship proGrams. Clin Infect Dis 59[Suppl 3]:S134–S145
23. Arena F, Viaggi B, Galli L et al (2015) Antibiotic susceptibility testing: present and future. Pediatr Infect Dis J 34:1128–1130
24. Banerjee R, Özenci V, Patel R (2016) Individualized approaches are needed for optimized blood cultures. Clin Infect Dis 63:1332–1339
25. Kostrzewa M, Sparbier K, Maier T et al (2013) MALDI-TOF MS: an upcoming tool for rapid detection of antibiotic resistance in microorganisms. Proteomics Clin Appl 7:767–778
26. Gaibani P, Galea A, Fagioni M et al (2016) Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of KPC-producing Klebsiella pneumoniae. J Clin Microbiol 54:2609–2613
27. Salimnia H, Fairfax MR, Lephart PR et al (2016) Evaluation of the filmarray blood culture identification panel: results of a multicenter controlled trial. J Clin Microbiol 54:687–698
28. Leone M, Malavieille F, Papazian L et al (2013) Routine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia. Crit Care 17(4):R170
29. Dureau AF, Duclos G, Antonini F et al (2017) Rapid diagnostic test and use of antibiotic against methicillin-resistant Staphylococcus aureus in adult intensive care unit. Eur J Clin Microbiol Infect Dis 36(2):267–272
30. Cambau E, Durand-Zaleski I, Bretagne S et al (2017) Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Med. doi:10.1007/s00134-017-4766-4
31. Schnabel RM, Boumans ML, Smolinska A et al (2015) Electronic nose analysis of exhaled breath to diagnose ventilator-associated pneumonia. Respir Med 109(11):1454–1459
32. Montuschi P, Mores N, Trove A et al (2013) The electronic nose in respiratory medicine. Respir Int Rev Thorac Dis 85(1):72e84
33. Hanson CW 3rd, Thaler ER (2005) Electronic nose prediction of a clinical pneumonia score: biosensors and microbes. Anesthesiology 102(1):63–68
34. Hockstein NG, Thaler ER, Torigian D et al (2004) Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope 114(10):1701–1705
35. Bassetti M, De Waele JJ, Eggimann P et al (2015) Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41(5):776–795. doi:10.1007/s00134-015-3719-z
36. Grall N, Massias L, Nguyen TT et al (2013) Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother 57:5423–5425. doi:10.1128/AAC.00039-13
37. van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415. doi:10.1056/NEJMoa1205037
38. Vollaard EJ, Clasener HA (1994) Colonization resistance. Antimicrob Agents Chemother 38:409–414
39. Gosalbes MJ, Vázquez-Castellanos JF, Angebault C et al (2016) Carriage of Enterobacteria producing extended-spectrum β-lactamases and composition of the gut microbiota in an Amerindian Community. Antimicrob Agents Chemother 60:507–514. doi:10.1128/AAC.01528-15
40. Donskey CJ, Chowdhry TK, Hecker MT et al (2000) Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med 343:1925–1932. doi:10.1056/NEJM200012283432604
41. Bhalla A, Pultz NJ, Ray AJ et al (2003) Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, Gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 24:644–649. doi:10.1086/502267
42. Bernard J, Armand-Lefèvre L, Luce E et al (2016) Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae. Clin Microbiol Infect 22(7):646.e1–4. doi:10.1016/j.cmi.2016.04.015
43. Ruppé E, Lixandru B, Cojocaru R et al (2013) Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother 57:4512–4517. doi:10.1128/AAC.00238-13
44. Woerther P-L, Micol J-B, Angebault C et al (2015) Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. J Med Microbiol 64:676–681. doi:10.1099/jmm.0.000078
45. Ruppé E, Armand-Lefèvre L, Estellat C et al (2015) High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics. Clin Infect Dis 61:593–600. doi:10.1093/cid/civ333
46. Weiss E, Zahar J-R, Lesprit P et al (2015) Elaboration of a consensual definition of de-escalation allowing a ranking of β-lactams. Clin Microbiol Infect 21:649. doi:10.1016/j.cmi.2015.03.013
47. Kaleko M, Bristol JA, Hubert S et al (2016) Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe 41:58–67. doi:10.1016/j.anaerobe.2016.05.015
48. de Gunzburg J, Ducher A, Modess C et al (2015) Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: a proof of concept study in healthy subjects. J Clin Pharmacol 55:10–16. doi:10.1002/jcph.359
49. Grall N, Massias L, Nguyen TT et al (2013) Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother 57:5423–5425. doi:10.1128/AAC.00039-13
50. Manges AR, Steiner TS, Wright AJ (2016) Fecal microbiota transplantation for the intestinal decolonization of extensively antimicrobial-resistant opportunistic pathogens: a review. Infect Dis Lond Engl 48:587–592. doi:10.1080/23744235.2016.1177199
51. Stool transplantation to reduce antibiotic resistance transmission. https://clinicaltrials.gov/ct2/show/NCT02461199. Accessed 10 July 2017
52. Fecal transplant for MDR pathogen decolonization. https://clinicaltrials.gov/ct2/show/NCT02906774. Accessed 10 July 2017
53. FMT for multidrug resistant organism reversal. https://clinicaltrials.gov/ct2/show/NCT02312986. Accessed 10 July 2017
54. Biotherapy for MRSA enterocolitis. https://clinicaltrials.gov/ct2/show/NCT02390622. Accessed 10 July 2017
55. FMT for MDRO colonization after infection in renal transplant recipients. https://clinicaltrials.gov/ct2/show/NCT02922816. Accessed 10 July 2017
56. Khanna S, Pardi DS, Kelly CR et al (2016) A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 214:173–181. doi:10.1093/infdis/jiv766
57. Bar-Yoseph H, Hussein K, Braun E (2016) Natural history and decolonization strategies for ESBL/carbapenem-resistant Enterobacteriaceae carriage: systematic review and meta-analysis. J Antimicrob Chemother 71:2729–2739
58. Buffie CG, Bucci V, Stein RR et al (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. doi:10.1038/nature13828
59. d’Herelle F (1931) Bacteriophage as a treatment in acute medical and surgical infections. Bull N Y Acad Med 7:329–348
60. Reardon S (2014) Phage therapy gets revitalized. Nat News 510:15. doi:10.1038/510015a
61. Wright A, Hawkins CH, Anggård EE et al (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349–357. doi:10.1111/j.1749-4486.2009.01973.x
62. Sarker SA, Sultana S, Reuteler G et al (2016) Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4:124–137. doi:10.1016/j.ebiom.2015.12.023
63. Standard treatment associated with phage therapy versus placebo for diabetic foot ulcers infected by S. aureus. https://clinicaltrials.gov/ct2/show/NCT02664740. Accessed 10 July 2017
64. Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa wound infections in burned patients. https://clinicaltrials.gov/ct2/show/NCT02116010. Accessed 10 July 2017
65. Verbeken G, De Vos D, Vaneechoutte M et al (2007) European regulatory conundrum of phage therapy. Future Microbiol 2:485–491. doi:10.2217/17460913.2.5.485
66. Bikard D, Euler CW, Jiang W et al (2014) Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nat Biotechnol 32:1146–1150. doi:10.1038/nbt.3043
67. Jun SY, Jung GM, Yoon SJ et al (2014) Preclinical safety evaluation of intravenously administered SAL200 containing the recombinant phage endolysin SAL-1 as a pharmaceutical ingredient. Antimicrob Agents Chemother 58:2084–2088. doi:10.1128/AAC.02232-13
68. Jun SY, Jung GM, Yoon SJ et al (2013) Antibacterial properties of a pre-formulated recombinant phage endolysin, SAL-1. Int J Antimicrob Agents 41:156–161. doi:10.1016/j.ijantimicag.2012.10.01
69. Czaplewski L, Bax R, Clokie M et al (2016) Alternatives to antibiotics—a pipeline portfolio review. Lancet Infect Dis 16:239–251. doi:10.1016/S1473-3099(15)00466-1
70. Mellata M, Mitchell NM, Schödel F et al (2016) Novel vaccine antigen combinations elicit protective immune responses against Escherichia coli sepsis. Vaccine 34:656–662. doi:10.1016/j.vaccine.2015.12.014
71. Cywes-Bentley C, Skurnik D, Zaidi T et al (2013) Antibody to a conserved antigenic target is protective against diverse prokaryotic and eukaryotic pathogens. Proc Natl Acad Sci USA 110:E2209–E2218. doi:10.1073/pnas.1303573110
72. Warrener P, Varkey R, Bonnell JC et al (2014) A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models. Antimicrob Agents Chemother 58:4384–4391. doi:10.1128/AAC.02643-14
73. Hua L, Hilliard JJ, Shi Y et al (2014) Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108–1117. doi:10.1128/AAC.02190-13
74. Skurnik D, Roux D, Pons S et al (2016) Extended-spectrum antibodies protective against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71:927–935. doi:10.1093/jac/dkv448
75. Lowy I, Molrine DC, Leav BA et al (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205. doi:10.1056/NEJMoa0907635
76. Cdiffense: Clostridium difficile vaccine trial. http://www.cdiffense.org/. Accessed 10 July 2017
77. Skurnik D, Cywes-Bentley C, Pier GB (2016) The exceptionally broad-based potential of active and passive vaccination targeting the conserved microbial surface polysaccharide PNAG. Expert Rev Vaccines 15:1041–1053. doi:10.1586/14760584.2016.1159135
78. Shu M-H, MatRahim N, NorAmdan N et al (2016) An Inactivated Antibiotic-Exposed Whole-Cell Vaccine Enhances bactericidal activities against multidrug-resistant Acinetobacter baumannii. Sci Rep 6:22332. doi:10.1038/srep22332
79. AMR Review. https://amr-review.org/Publications. Accessed 23 Jan 2017
80. Köhler T, Perron GG, Buckling A et al (2010) Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog 6:e1000883. doi:10.1371/journal.ppat.1000883
81. van Delden C, Köhler T, Brunner-Ferber F et al (2012) Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial. Intensive Care Med 38:1118–1125. doi:10.1007/s00134-012-2559-3
82. Crowther GS, Baines SD, Todhunter SL et al (2013) Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 68:168–176. doi:10.1093/jac/dks359